People with mild cognitive impairment, where thinking changes exist but daily independence stays largely intact, cannot join the LiBBY THC-CBD agitation trial. LiBBY tested THC and CBD for agitation in late-stage dementia with hospice care, not MCI, and enrollment is complete.
LiBBY stands for Life's End Benefits of cannaBidiol and tetrahYdrocannabinol. THC means tetrahydrocannabinol and CBD means cannabidiol. Researchers shared first topline results at AAIC 2026 in London on July 14, 2026, according to the Alzheimer's Association announcement the Alzheimer's Association announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Does MCI Not Qualify for LiBBY?
- What Did LiBBY Test and Find?
- Do Results Support Trying Cannabis for MCI?
- Where Can People With MCI Find Studies?
Why Does MCI Not Qualify for LiBBY?
The Alzheimer's Association reports LiBBY enrolled 120 people with Alzheimer's or other dementia and clinically significant agitation. All participants were hospice-eligible or already receiving hospice care. That profile differs sharply from typical MCI.
The National Institute of Neurological Disorders and Stroke describes MCI as a stage between normal aging changes and dementia. In dementia, thinking loss interferes with daily life, while independence stays largely intact in MCI. Hospice-eligible dementia care therefore excludes typical MCI.
- diagnosis of Alzheimer's or other dementia, not MCI
- clinically significant agitation
- hospice-eligible or receiving hospice care
What Did LiBBY Test and Find?
The study ran at 10 U.S. sites with an average age of 80, NeurologyLive reports in the NeurologyLive summary. Participants received placebo or 2 mg THC plus 100 mg CBD in digestible oil twice daily for 12 weeks.
Study visits occurred at home or in the residence. NeurologyLive reports active treatment met the primary and key secondary goals. The Cohen-Mansfield Agitation Inventory, a scale that rates agitation behaviors, fell more with THC-CBD by week 2 and stayed lower through week 12. Clinicians reported improvement in 83.9% at week 2 and 87.2% at week 12, versus 30.5% and 23.6% on placebo.
Do Results Support Trying Cannabis for MCI?
The LiBBY Study official site states findings apply only to its specific purified oral dose and delivery system. They do not extend to dispensary or over-the-counter cannabis, with details on the LiBBY Study results page. Do not copy the trial dose on your own for memory changes.
NeurologyLive reports similar overall adverse-event rates but more serious events with THC-CBD. Serious events occurred in 23.3% versus 11.9%, and deaths in 13.1% versus 5.1%, none judged drug-related. Those outcomes reflect a frail end-of-life population, not people living independently with MCI.
Where Can People With MCI Find Studies?
People with MCI can seek studies built for early memory changes rather than end-of-life agitation. Alzheimer's.gov reports TrialMatch matches cognitively impaired, caregiver, and healthy participants to studies, described on the TrialMatch page.
The same resource points to NIA's ADEAR Center for personal help. Start with one promising match and contact its study team directly. TrialMatch includes studies for caregivers and healthy volunteers as well as people with thinking changes.
- gather diagnosis, medications, and daily-function examples
- create a TrialMatch profile and review matched studies
- contact NIA's ADEAR Center with questions
- ask about MCI, caregiver, and healthy-volunteer options
You Might Also Like
- AAIC 2026 LiBBY THC-CBD Agitation Trial: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Research Participation Questions for People With Mild Cognitive Impairment
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
